Document Detail


Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 4th communication: improvement of heart failure of rats with myocardial infarction by valasartan.
MedLine Citation:
PMID:  9205776     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The hemodynamic effects of valsartan ((S)-N-valeryl-N-¿[2'-(1H-tetrazol-5-yl)bipheneoyl-4-yl]meth yl¿valine, CAS 137862-53-4, CGP 48933), a new angiotensin II type 1 receptor antagonist, on rats with myocardial infarction induced by coronary artery ligation was examined. Four weeks after ligation, mean blood pressure, left ventricular pressure and cardiac output decreased, while left ventricular end-diastolic pressure increased in control rats. Left ventricular end-diastolic pressure significantly decreased in rats treated with valsartan at 30 mg/kg/d p.o. for 4 weeks. Total systemic resistance remarkably decreased in those with enalapril 3 mg/kg/d p.o. and valsartan 30 mg/kg/d p.o. Valsartan and enalaprilat did not affect cardiac functions of isolated intact rat hearts before and after ischemia in Langendorff apparatus. In addition to hemodynamic effects observed in vivo, valsartan at 30 mg/kg p.o. significantly inhibited left ventricular hypertrophy. Valsartan would thus appear to be clinically useful for treating heart failure following myocardial infarction.
Authors:
N Hayashi; Y Fujimura; S Yamamoto; M Kometani; K Nakao
Related Documents :
349486 - Heart rate and cardiac function curves. their dependence on the age of the myocardium a...
6427866 - Non-potentiation of myocardial lesions by isoproterenol in t. cruzi-infected rats.
11205966 - Effect of glibenclamide and glimepiride treatment on the development of myocardial infa...
15623436 - The plasminogen-mmp system is more activated in the scar than in viable myocardium 3 mo...
349486 - Heart rate and cardiac function curves. their dependence on the age of the myocardium a...
10613566 - Cava endoluminal balloon occlusion as an adjunct technique to perform less invasive car...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Arzneimittel-Forschung     Volume:  47     ISSN:  0004-4172     ISO Abbreviation:  Arzneimittelforschung     Publication Date:  1997 May 
Date Detail:
Created Date:  1997-08-13     Completed Date:  1997-08-13     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0372660     Medline TA:  Arzneimittelforschung     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  625-9     Citation Subset:  IM    
Affiliation:
Drug Discovery Research Unit, Ciba-Geigy Japan Ltd., Takarazuka, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antihypertensive Agents / pharmacology,  therapeutic use*
Blood Pressure / drug effects
Body Weight / drug effects
Cardiomegaly / physiopathology
Enalapril / pharmacology,  therapeutic use
Male
Myocardial Infarction / physiopathology*
Myocardial Ischemia / drug therapy*
Myocardial Reperfusion Injury / physiopathology
Organ Size / drug effects
Rats
Receptor, Angiotensin, Type 1
Receptor, Angiotensin, Type 2
Receptors, Angiotensin / antagonists & inhibitors*
Tetrazoles / pharmacology,  therapeutic use*
Valine / analogs & derivatives*,  pharmacology,  therapeutic use
Vascular Resistance / drug effects
Ventricular Function, Left / drug effects
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Receptor, Angiotensin, Type 1; 0/Receptor, Angiotensin, Type 2; 0/Receptors, Angiotensin; 0/Tetrazoles; 137862-53-4/valsartan; 7004-03-7/Valine; 75847-73-3/Enalapril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 3rd c...
Next Document:  Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 5th c...